Literature DB >> 8223092

Hepatotoxicity.

H J Zimmerman1.   

Abstract

Chemical hepatic injury may result from accidental or suicidal exposure to toxic agents in the home or at work or from adverse reactions to medicinal agents. Chemical hepatic injury can lead to acute or chronic syndromes. Acute injury may be cytotoxic, cholestatic, or mixed. Cytotoxic injury is characterized by necrosis, steatosis, or both. Cholestatic injury is characterized by arrested bile flow and may be associated with portal inflammation or may occur in a setting in which there is no evidence of inflammation. Chronic hepatic injury includes chronic active hepatitis, steatosis, phospholipidosis, veno-occlusive disease, several forms of cirrhosis, peliosis hepatis, and hepatic neoplasms. The mechanism for injury may be intrinsic toxicity of the agent, reaction of an unusually susceptible host, or a combination of the two factors. Unusual susceptibility may be the result of immunologic idiosyncrasy (hypersensitivity reaction) or injury from a toxic metabolite (metabolic idiosyncrasy) of the drug.

Entities:  

Mesh:

Year:  1993        PMID: 8223092

Source DB:  PubMed          Journal:  Dis Mon        ISSN: 0011-5029            Impact factor:   3.800


  9 in total

1.  Acute liver failure after treatment with nefazodone.

Authors:  M I Lucena; R J Andrade; A Gomez-Outes; M Rubio; M R Cabello
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 2.  Adverse drug reaction and concepts of drug safety in Ayurveda: An overview.

Authors:  Manjunath Ajanal; Shradda Nayak; Buduru Sreenivasa Prasad; Avinash Kadam
Journal:  J Young Pharm       Date:  2013-10-23

3.  Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant.

Authors:  N O Ku; S A Michie; R M Soetikno; E Z Resurreccion; R L Broome; R G Oshima; M B Omary
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Caffeine does not enhance radiosensitivity of normal liver tissue in vivo.

Authors:  Tie-Jun Wang; Zhong-Shan Liu; Zhao-Chong Zeng; Shi-Suo Du; Ming Qiang; Wei Jiang; Le-Yuan Zhou; Wei-Jie Ding; Hai-Ying Zeng
Journal:  Mol Biol Rep       Date:  2010-11-30       Impact factor: 2.316

5.  A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease.

Authors:  P Sorrentino; G Tarantino; A Perrella; P Micheli; O Perrella; P Conca
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

6.  In silico approaches in organ toxicity hazard assessment: current status and future needs in predicting liver toxicity.

Authors:  Arianna Bassan; Vinicius M Alves; Alexander Amberg; Lennart T Anger; Scott Auerbach; Lisa Beilke; Andreas Bender; Mark T D Cronin; Kevin P Cross; Jui-Hua Hsieh; Nigel Greene; Raymond Kemper; Marlene T Kim; Moiz Mumtaz; Tobias Noeske; Manuela Pavan; Julia Pletz; Daniel P Russo; Yogesh Sabnis; Markus Schaefer; David T Szabo; Jean-Pierre Valentin; Joerg Wichard; Dominic Williams; David Woolley; Craig Zwickl; Glenn J Myatt
Journal:  Comput Toxicol       Date:  2021-09-09

Review 7.  Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.

Authors:  Xiaomin Deng; James P Luyendyk; Patricia E Ganey; Robert A Roth
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468

8.  Protective effects of Centella asiatica leaf extract on dimethylnitrosamine‑induced liver injury in rats.

Authors:  Myung-Joo Choi; Hong-Mei Zheng; Jae Min Kim; Kye Wan Lee; Yu Hwa Park; Don Haeng Lee
Journal:  Mol Med Rep       Date:  2016-10-05       Impact factor: 2.952

9.  Development of a convenient in vivo hepatotoxin assay using a transgenic zebrafish line with liver-specific DsRed expression.

Authors:  Xiaoyan Zhang; Caixia Li; Zhiyuan Gong
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.